转自:一度医药2025年4月25日,康方生物与合作伙伴Summit Therapeutics的关键临床试验结果在肿瘤药领域引发了一场风波。康方生物首次披露了其PD-1/VEGF双特异性抗体ivonescimab与默沙东Keytruda头对头对比试验的总生存期(OS)数据,而这一结果令Summit的投资者大失所望,消息公布后,Summit纳斯达克股价暴跌近37%,直至交易暂停。截图来自:百度股市通...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.